| 2/14/2024 | BK | Bio-Rad Laboratories enters new five-year $200 million revolver
|
| 2/24/2022 | IG | New Issue: Bio-Rad details $1.2 billion two-part sale of notes due 2027, 2032
|
| 2/23/2022 | IG | New Issue: Bio-Rad sells $1.2 billion of notes in two parts due 2027, 2032
|
| 2/23/2022 | BKIG | Moody's gives Bio-Rad, notes Baa2
|
| 2/23/2022 | BKIG | Fitch assigns Bio-Rad notes BBB
|
| 2/23/2022 | IG | Bio-Rad to sell dollar senior notes via seven bookrunners
|
| 2/23/2022 | BKIG | S&P gives Bio-Rad notes BBB
|
| 11/29/2021 | PV | Bio-Rad Laboratories loans €400 million to Sartorius-Herbst
|
| 8/20/2019 | BKIG | Fitch ups Bio-Rad to BBB
|
| 6/27/2019 | IG | S&P downgrades Apoteket
|
| 6/27/2019 | BKIG | Moody's upgrades Bio-Rad
|
| 4/18/2019 | BKIG | Fitch rates Bio-Rad revolver BBB-
|
| 4/16/2019 | BK | Bio-Rad Laboratories enters five-year $200 million revolver
|
| 7/27/2018 | BKIG | Fitch affirms Bio-Rad Laboratories
|
| 7/3/2018 | BKIG | Moody’s changes Bio-Rad view
|
| 5/29/2015 | BKIG | S&P: Bio-Rad business risk ‘fair’
|
| 7/17/2014 | BKHYIG | Moody’s lifts Bio-Rad to Baa3
|
| 6/26/2014 | BK | Bio-Rad Laboratories arranges $200 million revolver via JPMorgan
|
| 9/20/2013 | HYLM | Bio-Rad calls $300 million of 8% senior subordinated notes due 2018
|
| 4/9/2012 | BKHYIG | Moody's: Bio-Rad view positive
|
| 11/18/2011 | IG | Fitch affirms Bio-Rad
|
| 12/7/2010 | IG | S&P rates Bio-Rad notes BBB
|
| 12/6/2010 | HYIG | Moody's rates Bio-Rad notes Ba1
|
| 12/6/2010 | HYIG | Fitch rates Bio-Rad, loans BBB-, notes BBB- and BB+
|
| 12/6/2010 | HYIGLM | Bio-Rad plans to redeem its $425 million 71/2%, 6 1/8% senior notes
|
| 12/6/2010 | IG | Bio-Rad Labs files automatic shelf registration for debt securities
|
| 12/6/2010 | IG | Market Commentary: IBM, CIBC, Carlisle, NAB among sellers in hot primary; AT&T, Verizon flat on downgrades
|
| 12/6/2010 | HYIG | New Issue: Bio-Rad sells $425 million 4.875% 10-year senior notes at Treasuries plus 200 bps
|
| 6/25/2010 | BK | Bio-Rad Laboratories gets $200 million amended and restated revolver
|
| 4/30/2010 | HYIG | S&P upgrades Bio-Rad
|
| 1/6/2010 | BKHY | Moody's upgrades Bio-Rad
|
| 5/27/2009 | HY | Market Commentary: American Tower, Harrah's, AMC price, deal lifts existing Harrah's; Verso, Virgin, Terex slate
|
| 5/21/2009 | HY | Market Commentary: Apria leads six-deal, $2.44 billion day; GMAC, Quiksilver up again; funds gain $368 million
|
| 5/20/2009 | HY | Market Commentary: MarkWest, Hughes price; market awaits Gibson, upsized Apria; GMAC up on aid talk, Hertz gains
|
| 5/20/2009 | BK | Bio-Rad loan amendment becomes effective, revising leverage ratio
|
| 5/19/2009 | BKHY | S&P gives Bio-Rad notes BB+
|
| 5/19/2009 | BKHY | Moody's assigns Bio-Rad notes Ba3
|
| 5/19/2009 | HY | New Issue: Bio-Rad sells $300 million 8% notes due September 2016 at 98.25 to yield 8.321%
|
| 5/19/2009 | HY | Market Commentary: WMG, Ashland lead as deal barrage goes on; Bio-Rad, Ashland up; numbers lift Pilgrim's Pride
|
| 5/18/2009 | BKHY | Moody's affirms Bio-Rad
|
| 4/23/2009 | IG | S&P: Bio-Rad outlook positive
|
| 1/14/2008 | BKHYIG | S&P raises Bio-Rad to investment grade
|
| 10/3/2007 | BK | Bio-Rad amends loan, increasing amount of permissible borrowings to $200 million
|
| 5/17/2007 | BKHY | S&P affirms Bio-Rad
|
| 9/7/2006 | BT | Bio-Rad buys Provalis' medical diagnostics business for $3 million
|
| 8/14/2006 | BT | Ciphergen to sell proteomics instrument business to Bio-Rad for $20 million; will focus on diagnostics
|
| 2/13/2006 | BT | Roche, Applied Biosystems settle litigation with Bio-Rad Laboratories
|
| 11/16/2005 | BT | Bio-Rad gets FDA approval of software that supports FDA-approved BioPlex System
|
| 10/25/2005 | BT | Bio-Rad, Caliper collaborate to develop new microfluids platform
|
| 6/24/2005 | BKBT | Bio-Rad gets $150 million amended, restated revolver
|
| 12/13/2004 | BKHY | Moody's rates Bio-Rad notes Ba3
|
| 12/13/2004 | BKHY | S&P rates Bio-Rad notes BB-
|
| 12/13/2004 | HY | New Issue: Bio-Rad Laboratories sells $200 million 10-year notes at par to yield 6 1/8%
|
| 12/13/2004 | HY | Market Commentary: Bombardier off as CEO is axed; Reliant downsizes $1 billion-plus bond deal
|
| 12/24/2003 | HY | Market Commentary: BSE outbreak causes meat-bond holders to have a cow; Parmalat slides further
|
| 8/15/2003 | HY | GrafTech brings July, August note exchanges to $30 million
|
| 8/8/2003 | HY | Market Commentary: Three deals price, fourth scrubbed; outflow throws damper over market
|
| 8/6/2003 | HY | New Issue: Bio-Rad upsizes 10-year notes to $225 million, yield 71/2%
|
| 8/6/2003 | HY | Market Commentary: Upsized Bio-Rad, downsized Fisher Scientific among pricing deals; Calpine little moved on numbers
|
| 8/5/2003 | HY | Bio-Rad $200 million 10-year notes talked at 7 1/8%-7 3/8%, pricing Wednesday
|
| 8/5/2003 | HY | Market Commentary: Hilcorp prices downsized deal, Concentra also completed; aaiPharma gains on merger news
|
| 7/31/2003 | HY | S&P rates Flender notes B-
|
| 7/28/2003 | BKHY | Moody's raises Dade Behring outlook
|
| 7/28/2003 | HY | Bio-Rad starts roadshow for $200 million 10-year notes via Goldman Sachs
|
| 7/28/2003 | HY | Market Commentary: Slate keeps fattening, but no pricings; Oregon Steel off on delayed conference call
|
| 7/28/2003 | HY | Dynegy lenders OK restructure moves, including note tender offers
|
| 7/17/2003 | HY | Bio-Rad to sell $200 million notes to fund tender
|
| 7/17/2003 | HY | Nextel to redeem 10.65% notes and 11 1/8% preferred with $1 billion deal proceeds
|
| 5/6/2003 | BKHY | S&P upgrades Bio-Rad
|
| 2/27/2002 | HY | Moody's cuts AT&T Canada to junk, still on review
|
